Clinical Trial Update: Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant furmonertinib with cisplatin/pemetrexed in EGFR-mutated resectable NSCLC (stages IIIA-IIIB).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Furmonertinib (furmonertinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN